Osteoporosis remains a major cause of morbidity and mortality. Parathyroid hormone (PTH) is the only currently available therapy that substantially increases bone mass, but this therapy's effectiveness wanes with time. Our lack of understanding of the limitations of PTH therapy reflects very incomplete understanding of why PTH increases bone mass. We need to understand better the cellular targets of PTH and the intracellular mediators of PTH action. We propose to clarify both the cellular targets of PTH action and to identify a previously missed link in the action of PTH on osteocytes.
In Aim 1, we propose to characterize early cells of the osteoblast lineage in vivo. These cells are likely PTH targets (direct and indirect), but our ability to identify these cells and study how PTH changes them in vivo is limited. We will mark such early cells in the osteoblast lineage with a collagen 11-creERt transgene that will activate expression of a red fluorescent marker (tandem dimer tomato). We will determine the fates of such cells (how they differentiate into osteoblasts and adipocytes, how they proliferate and die, whether they participate in fracture repair). We will define their gene expression and will study how PTH changes their fates and activities in ways that may clarify the anabolic action of PTH and its limitations. We will also study bone lining cells to identify how PTH activates these cells to become active osteoblasts.
In Aim 2, we will study the roles of class IIa histone deacetylases (HDACs) in mediating PTH's action to suppress expression of sclerostin, a powerful inhibitor of wnt signaling secreted by osteocytes. We have shown that these HDACs mediate PTHrP's action in chondrocytes and hypothesize that, as in chondrocytes, HDACs respond to PTH by moving to the nucleus and suppressing transcription by Mef2 transcription factors. We will test this hypothesis using an osteocyte cell line from Dr. Divieti Pajevic and using knockout mice. We view sclerostin regulation as a model for many actions of PTH on all cells of the osteoblast lineage. Thus, by defining early cells of the lineage and a novel mediator of PTH signaling, we hope to clarify the mechanisms that can lead to more effective therapies.

Public Health Relevance

Parathyroid hormone (PTH) is a powerful but limited therapy for osteoporosis. Our goal is to define early cells of the lineage of bone-forming cells that mediate actions of PTH and to define a signaling pathway key to the actions of PTH. With this work we hope to provide tools needed to develop more effective osteoporosis therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK011794-50
Application #
9392547
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
50
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
Christov, Marta; Clark, Abbe R; Corbin, Braden et al. (2018) Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities. JCI Insight 3:
Dedic, Christopher; Hung, Tin Shing; Shipley, Alan M et al. (2018) Calcium fluxes at the bone/plasma interface: Acute effects of parathyroid hormone (PTH) and targeted deletion of PTH/PTH-related peptide (PTHrP) receptor in the osteocytes. Bone 116:135-143
Mizuhashi, Koji; Ono, Wanida; Matsushita, Yuki et al. (2018) Resting zone of the growth plate houses a unique class of skeletal stem cells. Nature 563:254-258
Hanna, Patrick; Grybek, Virginie; Perez de Nanclares, Guiomar et al. (2018) Genetic and Epigenetic Defects at the GNAS Locus Lead to Distinct Patterns of Skeletal Growth but Similar Early-Onset Obesity. J Bone Miner Res 33:1480-1488
Wein, Marc N; Foretz, Marc; Fisher, David E et al. (2018) Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential. Trends Endocrinol Metab 29:723-735
Bastepe, Murat (2018) GNAS mutations and heterotopic ossification. Bone 109:80-85
Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2017) Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts. J Bone Miner Res 32:892-901
Roszko, Kelly L; Bi, Ruiye; Gorvin, Caroline M et al. (2017) Knockin mouse with mutant G?11 mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors. JCI Insight 2:e91079
Grigelioniene, Giedre; Nevalainen, Pasi I; Reyes, Monica et al. (2017) A Large Inversion Involving GNAS Exon A/B and All Exons Encoding Gs? Is Associated With Autosomal Dominant Pseudohypoparathyroidism Type Ib (PHP1B). J Bone Miner Res 32:776-783
Balani, Deepak H; Ono, Noriaki; Kronenberg, Henry M (2017) Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Invest 127:3327-3338

Showing the most recent 10 out of 215 publications